September 3, 2010pfizer

thumbnail
Tuesday News

Icon Profits Flat

July 27, 2010

A commercial North Carolina institutional review board (IRB), Copernicus Group IRB, has received ISO 9001 certification. The company has a paperless system to manage clinical trial forms. “To our knowledge, CGIRB is the only central IRB that has achieved this certification. It is further evidence to our clients and the subjects of research studies that the quality of our services and our strong business practices are unsurpassed,” said Bruce Tomason, CEO. Here's a release. There's a split between early- and late-phase contract research organizations (CROs), according to this wire service article. Some small sponsors and biotechnology firms are delaying the launch of projects, analysts say, favoring late-phase specialists. Health Decisions, a technology-oriented contract research organization, appointed a new chief technology officer, Bryan Minihan. He'll be working on the company's system that, among other features, supports adaptive clinical trials. Minihan previously worked at GSK, Accenture, Intuit, and Cisco. “I’m excited to be…more...

thumbnail
Pfizer Supplier

Kforce On CRA Retention

July 09, 2010

Large life science companies have fired untold tens of thousands of employees during every year of the ongoing downturn—a period of both financial chaos and pharmaceutical mega-mergers. Here's one estimate, and…more...

thumbnail
Pfizer's Michael Ibara

Toward A Neutral AE Facilitator

April 23, 2010

Some people are happy with incremental progress. A long career in drug safety has left Michael Ibara searching for a bigger leap forward. He's the architect of a potential alternative to…more...

thumbnail
Vagelos Podcast

Merck’s Wise Man

May 29, 2009

Most of the ClinPage podcasts are done in a pretty typical Q&A format. Today, however, we're posting a different type of audio: some snippets from the 2009 Clinical Trials Congress, held…more...

thumbnail
Whale Watching

Projecting Pfizer Revenues

March 10, 2009

The best minds on Wall Street like Pfizer’s $68 billion acquisition of Wyeth. Last week, to take just one example, a prominent firm (which advised Pfizer on the merger) said it believes its client is poised for a revival once it has Wyeth drugs in its pipeline.Yesterday, Merck took a page from the same play book, buying…more...

thumbnail
Lilly, Centocor, Pfizer

2009 Clinical Trials Congress

February 11, 2009

One surprising aspect of the clinical trial landscape is just how few PhDs and physicians share their knowledge, either as industry insiders or academic researchers. The vastness of the global research enterprise does necessarily involve large numbers of other professionals. We know that. But hearing from the experts now and then is nice. We get a large…more...

thumbnail
R U Txtng Px Yet?

Pfizer Picks Exco SMS

December 12, 2008

Say you need someone to do something for you in Singapore. It turns out it’s rude to leave someone a few voice mail messages. Even several email requests are a bit of a no-no. Instead, communication via so-called “text” or short messaging systems (SMS) is the norm and the Emily-Post approved technique. That works for Pfizer. The…more...

thumbnail
Great '08 Contraction

Pfizer, GSK Reassess R&D

October 01, 2008

Yesterday, Pfizer announced that it was abandoning new projects in cardiovascular disease. This was about as expected as Federal Express investing in horse-based shipping routes. Then GSK leaked word it was cutting 850 jobs, or 6 percent of its R&D headcount, in the wake of an arrival of a new CEO, Andrew Witty, and the quiet departures…more...

Pharmica, Merck, Genzyme Strategies

Finding The Right Metrics

What to count (or not), and why.

Strategies from Wyeth, Actelion & Pfizer

CTC 2008: Proactive Risk Abatement

A report from the Clinical Trials Congress about risk. One message: start a regulatory conversation early. And consult your preclinical team.

A Tale Of Two CROs

Pfizer Tackles Clinical Efficiency

With impressive numbers, Pfizer’s Mike Collins talked about how the company is streamlining its clinical trial process.

Goal: Improve Investigator Ties

Wyeth’s Site Initiative

Sponsors are abuzz about site relationship management (SRM). In the first installment of our series, Wyeth describes its efforts to become the sponsor of choice.

Who Should Not Recruit?

Clarification: Pfizer Site Strategy

A clarification to recent ClinPage coverage of Pfizer at DIA.

Our Revised Story

Pfizer: Dance With Only Me

A clarification of our report from DIA.

MDS, bad eDiary data, Pfizer

News Briefs

News for June 1.


© 2010 ClinPage. All Rights Reserved.